ABT240705P65000
- 0.01
- 0.000.00%
Abbott Laboratories Newsroom
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Did Your Heart Skip a Beat? Your Wearable Knows. -- Barrons.com
Express News | FDA Says Abbott Medical Issues Correction For HeartMate LVAS System Monitor Due To Screen Issues That Could Cause Unintentional Pump Stop
Express News | FDA: Abbott Heartmate Lvas System Monitor Recall Involves Correcting Devices & Does Not Involve Removing Them From Where They Are Used or Sold
Express News | FDA: There Have Been 14 Reported Injuries, No Reports of Death Related to Recall
Express News | FDA: Abbott Medical Issues Correction for Heartmate Lvas System Monitor Due to Screen Issues That May Cause Unintentional Pump Stop
Investors Heavily Search Abbott Laboratories (ABT): Here Is What You Need to Know
Market Whales and Their Recent Bets on ABT Options
Unusual Options Activity: CVS, DKNG and Others Attract Market Bets, CVS V/OI Ratio Reaches 137.5
Abbott Hosts Conference Call for Second-Quarter Earnings
Heart Just Skip a Beat? Your Watch Already Knows.
United States Molecular Diagnostics Market Report 2024-2032 Featuring F Hoffmann-la Roche, Illumina, Hologic, Agilent Technologies, Qiagen, Myriad Genetics, Abbott Laboratories, Danaher, BD & Co
Abbott (ABT) Exceeds Market Returns: Some Facts to Consider
Los Compradores De Ciertos Productos PediaSure En California Pueden Ver Afectados Sus Derechos Por Una Demanda Colectiva
Abbott's (ABT) EPD Expansion Continues Despite FX Headwind
The Zacks Analyst Blog Highlights Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130
BofA Securities Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Top Analyst Reports for Abbott, BP & Gilead
Epilepsy Drugs Market, Size, Global Research 2024-2030 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott Laboratories, Alkem Laboratories, Bausch, GSK, Novartis, and Pfizer - ResearchAndMarkets.com